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Abstract
Platelet-activating factor (PAF) plays an important role in the pathogenesis of sepsis, and the level of plasma PAF
acetylhydrolase (pPAF-AH), which inactivates PAF, decreases in sepsis patients except for the sepsis caused by severe
leptospirosis. Usually, increase of pPAF-AH activity was observed in lipopolysaccharide (LPS)-induced Syrian hamster and rat
sepsis models, while contradictory effects were reported for mouse model in different studies. Here, we demonstrated the in
vivo effects of LPS upon the change of pPAF-AH activity in C57BL/6 mice and Mongolian gerbils. After LPS-treatment, the
clinical manifestations of Mongolian gerbil model were apparently similar to that of C57BL/6 mouse sepsis model. The
pPAF-AH activity increased in C57BL/6 mice after LPS induction, but decreased in Mongolian gerbils, which was similar to
that of the human sepsis. It thus suggests that among the LPS-induced rodent sepsis models, only Mongolian gerbil could
be used for the study of pPAF-AH related to the pathogenesis of human sepsis. Proper application of this model might
enable people to clarify the underline mechanism accounted for the contradictory results between the phase II and phase III
clinical trials for the administration of recombinant human pPAF-AH in the sepsis therapy.
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Introduction
Platelet-activating factor (1-O-alkyl-2-acetyl-sn-glycero-3-phos-
phocholine, PAF), a potent proinflammatory phospholipid medi-
ator, has remarkably diverse biological effects in diseases [1],
including sepsis, which arises through body’s inflammation
response to infection and is a leading cause of death and disability
for patients in an intensive care unit [2]. PAF synthesis is up-
regulated in response to bacterial endotoxins both in vivo and in
vitro [3,4]. Although it was recently reported that PAF may protect
mice against lipopolysaccharide (LPS)-mediated sepsis [5], many
studies indicated that increased concentrations of PAF may
contribute to the deleterious effects of systemic inflammation in
the pathogenesis of severe sepsis [2].
The inactivation of PAF is mediated by PAF acetylhydrolase
(PAF-AH), a calcium-independent phospholipases A2 with
specificity for hydrolysis of this lipid mediator [6]. The plasma
form of PAF-AH (pPAF-AH) is a secreted protein in the blood that
serves to inactivate PAF and PAF-like phospholipids [6]. This
enzyme accounts for all of the PAF-inhibitory activity found in
human serum, limiting the normal serum half-life of PAF to only a
few minutes [1,7]. Except for the sepsis caused by severe
leptospirosis [8], the activity of pPAF-AH is diminished in human
sepsis [7,9,10,11] as a consequence of endotoxin and cytokine-
induced reduction of the pPAF-AH encoding gene transcription
and possible inactivation by oxidant injury [11,12].
A potential therapeutic strategy for sepsis is to facilitate the
inactivation of PAF with the supplement of pPAF-AH. The results
of the clinical trials of recombinant human pPAF-AH in patients
with severe sepsis were controversial (Table 1). In 2006, Gomes et
al. reported that the administration of exogenous recombinant
pPAF-AH reduced mortality and inflammatory injury relevant to
the clinical syndrome (Table 1), based on the depressed pPAF-AH
activity in C57BL/6 and Swiss mouse models induced by LPS or
cecal ligation and puncture (CLP) (Table 2). However, this result is
partly in contradictory to the previous studies in rodents
challenged with LPS, which showed an increase of pPAF-AH
activity in Syrian hamsters, rats, and C57BL/6 mice (Table 2).
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AH against LPS-treatment in mice, and/or explore alternative
animals suitable for simulating the role of pPAF-AH in human
sepsis.
Previously, we found that Mongolian gerbil has its normal
pPAF-AH level similar to that of human, and the patterns of the
change of PAF-AH level in serum during the course of severe
leptospirosis in gerbil model are similar to that of severe
leptospirosis patients, including the levels of elevation [8]. These
findings were consistent with the fact that LPS of Leptospira
interrogans is much less virulent than that of Escherichia coli, and has
little effect on the sepsis caused by leptospirosis [13]. Therefore,
among experimental rodents and rabbits, gerbil is likely to be a
good candidate to develop an animal model to mimic the role of
pPAF-AH in human diseases, particularly, the LPS-induced sepsis
[8]. In this study, we examined the in vivo effects of LPS on pPAF-
AH activity in C57BL/6 mice and gerbils.
Materials and Methods
Ethics Statement
All animals were handled in strict accordance with good animal
practice as defined by the relevant local animal welfare bodies, and
all animal work was approved by the Animal Research Committee
of the Chinese National Human Genome Center at Shanghai.
Animal Study
Male C57BL/6 mice (Shanghai Laboratory Animal Center,
China), one month of age (18 to 22 g), and male gerbils (Zhejiang
Laboratory Animal Center, China), two months of age (45 to
60 g), were given a standard laboratory diet and water ad libitum
and housed under controlled environmental conditions. LPS from
Escherichia coli (serotype 0111:B4) was purchased from Sigma
Chemical Company and was freshly diluted to desired concentra-
tions in pyrogen-free 0.9% saline. After a minimum 3-day
acclimation period, animals were intraperitoneally injected with
either saline (control) or LPS (3 or 5 mg/kg body weight).
pPAF-AH Activity Assay
pPAF-AH activity was determined by using a commercially
available assay kit (Cayman Chemical) according to manufactur-
er’s instructions. The assay uses 2-thio-PAF, which serves as a
substrate for pPAF-AH. On hydrolysis of the acetyl thioester
bond by pPAF-AH, free thiols are detected using 5, 59-dithio-bis-
(2-nitrobenzoic acid) (DTNB, Ellman’s reagent). The absorbance
is read at 405 nm over a period of time using an ELISA plate
reader.
Statistics. Data were analyzed with Graph-Pad Prism,
version 2.0 (GraphPad Software). Data were presented as mean
values 6 SEM. Statistical analyses were performed using one way
analysis of variance (ANOVA).
Results and Discussion
Compared to the control group (0 mg/kg body weight, saline
only), the C57BL/6 mice and gerbils with LPS-treatment (3 or
5 mg/kg body weight) appeared acutely ill and displayed signs of
lethargy, and then they were euthanized while the animals
appeared moribund after LPS-treatment (Table 3). Most of the
animals died after LPS injection, and autopsy showed the volume
increase of spleen in all the animals of both C57BL/6 mice and
gerbils (Table 3). Therefore, the clinical manifestations of LPS-
induced gerbil model were apparently similar to that of C57BL/6
mouse sepsis model [9].
Table 1. Therapeutic effects of the administration of recombinant human pPAF-AH in human sepsis patients and mouse models.
Status Year Effect Reference
Human Phase IIa 1999 Improvements in oxygenation and multiple organ dysfunction [20]
Phase IIb 2003 Striking survival advantage and other positive effects [21]
Phase III 2004 No effect on decreasing mortality [22]
Mouse LPS/CLP model 2006 Reduction of inflammatory injury and mortality [9]
Mouse represented the C57BL/6 mouse.
doi:10.1371/journal.pone.0009190.t001
Table 2. Response of pPAF-AH in LPS and CLP sepsis models.
Species Strain
Change of
pPAF-AH activity Reference
LPS model Hamster Syrian hamster q [14]
Rat Sprague-Dawley q [14,15,16,17]
Mouse C57BL/6 q [14], this work
C57BL/6 and Swiss Q [9]
Gerbil Mongolian gerbil Q This work
CLP model Mouse C57BL/6 and Swiss Q [9]
doi:10.1371/journal.pone.0009190.t002
Table 3. Clinical manifestations of C57BL/6 mice and gerbils
induced by LPS.
Dose
(mg/kg)
Clinical
observation
Death
/total
Time to
death (hr)
Mouse 0
a Normal 0/10 ND
3 Lethargy, diarrhea and
spleen volume increase
10/10 36-45
5 Lethargy, diarrhea and
spleen volume increase
10/10 15-26
Gerbil 0
a Normal 0/10 ND
3 Lethargy, diarrhea and
spleen volume increase
9/10 36-49
5 Lethargy, diarrhea and
spleen volume increase
10/10 13-27
Mouse represented the C57BL/6 mouse.
aControl, intraperitoneally injected with saline only.
ND, no animal death determined.
doi:10.1371/journal.pone.0009190.t003
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was measured. We found that both 3 and 5 mg/kg body weight
LPS induced the elevation of the pPAF-AH activity in C57BL/6
mice, and the elevated levels were similar in these two dose group
(Figure 1). In contrast, after LPS-treatment (3 or 5 mg/kg body
weight), the pPAF-AH activity of gerbils decreased compared to
that of the control, and the decreased levels were similar in the
doses of 3 and 5 mg/kg body weight (Figure 1).
Our result showed that LPS caused the elevation of pPAF-AH
activity in C57BL/6 mice (Figure 1), which was the same with that
reported by Memon et al. [14] (Table 2), but different from the
study of Gomes et al. [9] (Table 2). Although the reason for the
different effects of LPS in C57BL/6 mice was yet to be elucidated,
the present study, together with the studies in Syrian hamsters,
rats, and C57BL/6 mice challenged by LPS [14,15,16,17]
(Table 2), showed that, among rodent species, only the gerbil
demonstrated the decrease of pPAF-AH activity under the
exposure of LPS (Figure 1), which was similar to the response of
pPAF-AH measured in sepsis patients [7,9,10,11]. Therefore, the
LPS-induced sepsis in gerbil could be used to study the
pharmacological effect of recombinant pPAF-AH in sepsis, and
may provide pre-clinical evaluation of pPAF-AH in sepsis for the
additional clinical trials in the future.
LPS is a relatively pure compound that can be stably stored in
lyophilized form. Therefore, the LPS model is much easier to be
established than the surgical CLP model, which is the ‘‘gold
standard’’ in sepsis research [18]. However, the LPS model is
known to be different from the sepsis in human and CLP model
with respect to the profile of cytokine release [18,19]. PAF is a
phospholipid cytokine implicated in a wide range of biological and
pathologic responses [1], and thus, the different responses of
pPAF-AH, the regulator of serum PAF [6], between sepsis patients
and LPS models of Syrian hamster, rat and mouse (Table 2 and
Figure 1) might be accounted by the differences in the profile of
cytokine release. The similar responses of pPAF-AH between
sepsis patients and gerbil LPS model (Figure 1), as well as between
the severe leptospirosis patients and the gerbil leptospirosis model
[8], may implicate the similar response of cytokine release between
human and gerbil. This possible underline mechanism should be
further tested in order to fully characterize this novel model, which
is potentially advantageous in mimicking the cytokine response in
sepsis.
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